ATRX and neuroblastoma: Recent studies have shown that in neuroblastoma 68 % of ATRX mutations are multi-exon deletions, most commonly resulting in loss of exons 2–10 of the gene, and resulting in an in-frame fusion (IFF) protein with gain of function oncogenic effects [6,7].